Most "comprehensive" panels miss the things that actually move with age, and over-test the things that don't. A real longevity workup is shorter, sharper, and built around measurements that can be changed.
The standard physical you got at thirty-five doesn't change much by fifty-five. Cholesterol, glucose, a CBC, a few electrolytes. The labs are run because insurance pays for them, not because they're the most informative measurements available — and they routinely miss the metabolic, inflammatory, and cardiovascular drift that actually predicts the next decade.
The longevity biomarkers worth running are the ones that respond to intervention and predict outcomes. There are roughly twenty of them. Done correctly, they take a single morning's draw and recalibrate the next year of medical decision-making.
The four panels that matter
1. Advanced lipidology
Standard LDL is a poor predictor of cardiovascular risk. ApoB — the protein on every atherogenic lipoprotein — is the better measurement, and it's been the better measurement for twenty years. We pair ApoB with Lp(a) (genetic, lifetime risk), particle count and size (LDL-P), and remnant cholesterol. Together, those four predict cardiovascular events better than any single number on a standard panel.
2. Inflammation and metabolic stress
hs-CRP catches systemic inflammation that standard CRP rounds to zero. Fasting insulin and HOMA-IR catch insulin resistance years before fasting glucose drifts. GGT — long ignored — is one of the cleanest predictors of all-cause mortality once you know how to read it. None of these are exotic. All of them are missed.
3. Hormones, in context
Total testosterone is meaningless without SHBG. Free T3 is meaningless without reverse T3. DHEA-S, IGF-1, and morning cortisol round out a hormone panel that actually tracks the axes that drive performance, recovery, and cognition. We test hormones cyclically — same day, same time, same fasted state — to keep the signal clean across a longevity arc.
4. Cellular and methylation
Homocysteine flags methylation cycle stress. MTHFR genotype contextualizes it. Vitamin D (25-OH) and the omega-3 index quantify the two intake variables that move outcomes the most. For members on extended longevity arcs, we add a biological-age methylation clock at baseline and at twelve months — the only direct measurement we have of whether a protocol is, in the most literal sense, working.
| What it measures | Why most panels skip it | |
|---|---|---|
| ApoB | Atherogenic lipoprotein burden | Insurance prefers LDL-C |
| Lp(a) | Genetic lifetime CV risk | Run-once test, not a billing event |
| Fasting insulin / HOMA-IR | Insulin resistance, years pre-diabetes | Glucose seems normal |
| hs-CRP | Low-grade systemic inflammation | Standard CRP rounds it down |
| GGT | All-cause mortality predictor | Read poorly, dismissed often |
| Free T3 + reverse T3 | Functional thyroid status | TSH alone misses it |
| Homocysteine | Methylation cycle stress | Only run after a problem appears |
| Omega-3 index | Cardio-cognitive risk modifier | Patients aren't told it exists |
| Methylation age | Direct biological aging signal | Not yet billable, very real |
Frequency: how often is enough
Once a year is the floor for most members. Active longevity arcs — particularly those including Hyperbaric Oxygen Therapy, peptide therapy, or hormone optimization — get a midpoint draw at 90 days to confirm the protocol is moving the variables it should be moving, and to catch any drift early. Methylation age is run at baseline and twelve months; once or twice a year is sufficient.
The right panel, run with intention, is the most decision-changing morning your medical practice will ever schedule.
What to do with the results
A panel without a physician interpretation is just a PDF. Every BioHaus longevity panel comes with a structured read by Dr. Rosen — what's in range, what's drifting, what's flagged — and a one-page protocol delta. This is the working document. It governs the next quarter of your IVs, peptides, training prescription, sleep targets, and follow-up scheduling.
The point of a biomarker panel isn't to find a problem. It's to give a physician something precise enough to push against — before there's a problem to find.
